

## Accepted Manuscript

Impact of Cefazolin Co-administration with Vancomycin to Reduce Development of Vancomycin Intermediate Staphylococcus aureus

Nivedita B. Singh, Juwon Yim, Seyedehameneh Jahanbakhsh, George Sakoulas, Michael J. Rybak



PII: S0732-8893(18)30113-5  
DOI: doi:[10.1016/j.diagmicrobio.2018.03.020](https://doi.org/10.1016/j.diagmicrobio.2018.03.020)  
Reference: DMB 14572

To appear in:

Received date: 2 October 2017  
Revised date: 16 March 2018  
Accepted date: 29 March 2018

Please cite this article as: Nivedita B. Singh, Juwon Yim, Seyedehameneh Jahanbakhsh, George Sakoulas, Michael J. Rybak, Impact of Cefazolin Co-administration with Vancomycin to Reduce Development of Vancomycin Intermediate Staphylococcus aureus. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Dmb(2018), doi:[10.1016/j.diagmicrobio.2018.03.020](https://doi.org/10.1016/j.diagmicrobio.2018.03.020)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Impact of Cefazolin Co-administration with Vancomycin to Reduce Development of Vancomycin Intermediate *Staphylococcus aureus***

Nivedita B. Singh<sup>1</sup>, Juwon Yim<sup>1</sup>, Seyedehameneh Jahanbakhsh<sup>1</sup>, George Sakoulas<sup>4</sup>, Michael J. Rybak<sup>1,2,3</sup>

<sup>1</sup> Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA; <sup>2</sup> Department of Medicine, Division of Infectious Diseases, School of Medicine, Wayne State University, Detroit, MI, USA; <sup>3</sup> Department of Pharmacy Services, Detroit Medical Center, Detroit, MI, USA; <sup>4</sup> Division of Host-Microbe Systems and Therapeutics Center for Immunity, Infection and Inflammation, University of California San Diego School of Medicine, La Jolla, California, USA

**Key words:** MSSA, MRSA; VISA; Cefazolin; Vancomycin; Resistance

**Running title:** Cefazolin Vancomycin combination prevent VISA

**Corresponding author:** Michael J. Rybak, Pharm.D., M.P.H., Ph.D., Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Ave, Detroit, MI 48201, m.rybak@wayne.edu, (313) 577-4376.

Download English Version:

<https://daneshyari.com/en/article/8737199>

Download Persian Version:

<https://daneshyari.com/article/8737199>

[Daneshyari.com](https://daneshyari.com)